Stocks · News reference
Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 90 percent decrease over losses of $(0.10) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 8:14 PM
- Checked
- Aug 6, 2026, 8:14 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Corvus Pharmaceuticals director David Scott Moore purchased 21,700 common shares for approximately $250,000 on June 11, 2026, marking his first investment in the company since joining as a director in October. Moore also received 15,000 stock options vesting in a year. The insider buy is viewed as a positive signal, though it should be considered alongside other investment factors.
Read original at the-motley-foolCorvus Pharma Participates In New $13.5M Financing For Angel Pharmaceuticals
Read original at benzinga